Ost-müük Angion Biomedica Corp. - ANGN CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | 0.0802 | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.030779% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | -0.013666% | ||||||||
| Ööpäeva tasu aeg | 22:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Võtmestatistika
| Eelmine sulgemine* | 0.6746 |
| Avatud* | 0.6843 |
| Aastane muutus* | -71.37% |
| Päeva ulatus* | 0.6644 - 0.6844 |
| 52 nädala ulatus | 0.59-2.63 |
| Keskmine maht (10 päeva) | 73.80K |
| Keskmine maht (3 kuud) | 1.75M |
| Turukapitalisatsioon | 20.89M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 30.11M |
| Tulu | 28.24M |
| EPS | -0.58 |
| Dividendid (% kasumist) | N/A |
| Beeta | -100.00K |
| Järgmine tuluaruande kuupäev | Mar 28, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|---|---|---|---|---|---|
| Feb 7, 2023 | 0.6746 | 0.0001 | 0.01% | 0.6745 | 0.6785 | 0.6745 |
| Feb 6, 2023 | 0.6747 | 0.0200 | 3.05% | 0.6547 | 0.6747 | 0.6544 |
| Feb 3, 2023 | 0.6549 | 0.0169 | 2.65% | 0.6380 | 0.6747 | 0.6369 |
| Feb 2, 2023 | 0.6578 | -0.0263 | -3.84% | 0.6841 | 0.6846 | 0.6453 |
| Feb 1, 2023 | 0.6842 | 0.0088 | 1.30% | 0.6754 | 0.7039 | 0.6544 |
| Jan 31, 2023 | 0.6843 | 0.0002 | 0.03% | 0.6841 | 0.7039 | 0.6841 |
| Jan 30, 2023 | 0.6845 | 0.0002 | 0.03% | 0.6843 | 0.7138 | 0.6568 |
| Jan 27, 2023 | 0.6843 | 0.0464 | 7.27% | 0.6379 | 0.6846 | 0.6253 |
| Jan 26, 2023 | 0.6677 | 0.0423 | 6.76% | 0.6254 | 0.7042 | 0.6253 |
| Jan 25, 2023 | 0.6257 | -0.0390 | -5.87% | 0.6647 | 0.6825 | 0.6253 |
| Jan 24, 2023 | 0.6647 | 0.0000 | 0.00% | 0.6647 | 0.6747 | 0.6353 |
| Jan 23, 2023 | 0.6159 | 0.0003 | 0.05% | 0.6156 | 0.6552 | 0.6156 |
| Jan 20, 2023 | 0.6158 | -0.0196 | -3.08% | 0.6354 | 0.6356 | 0.5962 |
| Jan 19, 2023 | 0.6453 | -0.0098 | -1.50% | 0.6551 | 0.6649 | 0.5765 |
| Jan 18, 2023 | 0.6776 | -0.0079 | -1.15% | 0.6855 | 0.6855 | 0.6351 |
| Jan 17, 2023 | 0.6893 | -0.0144 | -2.05% | 0.7037 | 0.7431 | 0.6675 |
| Jan 13, 2023 | 0.9876 | 0.0984 | 11.07% | 0.8892 | 0.9876 | 0.8892 |
| Jan 12, 2023 | 0.9189 | 0.0390 | 4.43% | 0.8799 | 0.9240 | 0.8793 |
| Jan 11, 2023 | 0.8964 | 0.0049 | 0.55% | 0.8915 | 0.9191 | 0.8700 |
| Jan 10, 2023 | 0.9289 | -0.0001 | -0.01% | 0.9290 | 0.9340 | 0.8570 |
Angion Biomedica Corp. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Aastas
- Kvartalis
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Kogutulu | 4.029 | 1.487 | 2.88 | 28.312 |
| Tulu | 4.029 | 1.487 | 2.88 | 28.312 |
| Kulud, Kokku | 0.378 | 0.64 | 1.19 | 0.433 |
| Brutokasum | 3.651 | 0.847 | 1.69 | 27.879 |
| Kogu tegevuskulu | 18.371 | 40.078 | 58.153 | 66.714 |
| Müük/Üldine/admin kulud, kokku | 5.391 | 9.601 | 17.986 | 18.488 |
| Uuringud ja arendus | 12.602 | 29.837 | 38.977 | 48.698 |
| Tulud majandustegevusest | -14.342 | -38.591 | -55.273 | -38.402 |
| Intressitulud (kulu), muud tulud, neto | 0.401 | 0.488 | -8.249 | -2.191 |
| Muud, neto | -6.084 | -2.555 | -16.527 | -13.98 |
| Netotulu enne makse | -20.025 | -40.658 | -80.107 | -54.573 |
| Netotulu pärast makse | -20.025 | -40.658 | -80.107 | -54.573 |
| Netotulu enne erikulusid | -20.025 | -40.658 | -80.107 | -54.573 |
| Netotulu | -20.025 | -40.658 | -80.107 | -54.573 |
| Total Adjustments to Net Income | -4.98 | 0 | ||
| Arvestatav tulu, v a erikulud | -25.005 | -40.658 | -80.107 | -54.573 |
| Arvestatav tulu, koos erikuludega | -25.005 | -40.658 | -80.107 | -54.573 |
| Jaotamisele kuuluv netotulu | -25.005 | -40.658 | -80.107 | -54.573 |
| Keskmine jaotamisele kuuluv aktsia kohta | 9.97635 | 9.97635 | 14.7621 | 28.2448 |
| Jaotatav EPS, v a erakorralised kulud | -2.50643 | -4.07544 | -5.42652 | -1.93214 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
| Jaotamisele kuuluv normaal-EPS | -2.50643 | -4.07544 | -5.4226 | -1.96418 |
| Gain (Loss) on Sale of Assets | -0.058 | 0 | ||
| Ootamatud kulutused (tulu) | -0.905 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Kogutulu | 0.371 | 0.54 | 1.46 | 25.941 | 1.648 |
| Tulu | 0.371 | 0.54 | 1.46 | 25.941 | 1.648 |
| Kulud, Kokku | 0 | 0 | 0 | 0.433 | |
| Brutokasum | 0.371 | 0.54 | 1.46 | 25.508 | |
| Kogu tegevuskulu | 20.31 | 17.879 | 17.218 | 11.307 | 16.133 |
| Müük/Üldine/admin kulud, kokku | 6.012 | 4.34 | 3.93 | 4.206 | 4.466 |
| Uuringud ja arendus | 14.298 | 14.444 | 13.288 | 6.668 | 11.667 |
| Tulud majandustegevusest | -19.939 | -17.339 | -15.758 | 14.634 | -14.485 |
| Intressitulud (kulu), muud tulud, neto | -2.168 | 0.067 | -0.074 | -0.016 | 0.206 |
| Muud, neto | -14.58 | 0.2 | 0.128 | 0.272 | 0.039 |
| Netotulu enne makse | -36.687 | -17.072 | -15.704 | 14.89 | -14.24 |
| Netotulu pärast makse | -36.687 | -17.072 | -15.704 | 14.89 | -14.24 |
| Netotulu enne erikulusid | -36.687 | -17.072 | -15.704 | 14.89 | -14.24 |
| Netotulu | -36.687 | -17.072 | -15.704 | 14.89 | -14.24 |
| Arvestatav tulu, v a erikulud | -36.687 | -17.072 | -15.704 | 14.89 | -14.24 |
| Arvestatav tulu, koos erikuludega | -36.687 | -17.072 | -15.704 | 14.89 | -14.24 |
| Jaotamisele kuuluv netotulu | -36.687 | -17.072 | -15.704 | 14.89 | -14.24 |
| Keskmine jaotamisele kuuluv aktsia kohta | 23.4438 | 29.6703 | 29.8296 | 29.9654 | 29.9592 |
| Jaotatav EPS, v a erakorralised kulud | -1.56489 | -0.57539 | -0.52646 | 0.49691 | -0.47531 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -1.56489 | -0.60589 | -0.52646 | 0.49691 | -0.47531 |
| Ootamatud kulutused (tulu) | -0.905 | 0 | 0 | ||
| Gain (Loss) on Sale of Assets | 0 |
- Aastas
- Kvartalis
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Käibevarad kokku | 25.679 | 6.106 | 42.297 | 91.247 |
| Raha ja lühiajalised investeeringud | 25.512 | 5.571 | 34.607 | 88.756 |
| Raha ja ekvivalendid | 25.512 | 5.571 | 34.607 | 88.756 |
| Laekumata arved, neto | 0.107 | 0.44 | 5 | 0.806 |
| Prepaid Expenses | 0.06 | 0.095 | 0.352 | 1.031 |
| Total Assets | 26.628 | 11.886 | 47.347 | 96.513 |
| Property/Plant/Equipment, Total - Net | 0.017 | 4.781 | 4.228 | 4.437 |
| Property/Plant/Equipment, Total - Gross | 0.295 | 5.109 | 4.654 | 4.954 |
| Accumulated Depreciation, Total | -0.278 | -0.328 | -0.426 | -0.517 |
| Long Term Investments | 0.932 | 0.999 | 0.822 | 0.723 |
| Total Current Liabilities | 7.355 | 26.575 | 107.449 | 11.296 |
| Accounts Payable | 0.534 | 11.239 | 5.578 | 4.71 |
| Accrued Expenses | 2.98 | 3.694 | 7.276 | 4.113 |
| Notes Payable/Short Term Debt | 0 | 5.848 | 51.43 | 0 |
| Other Current Liabilities, Total | 3.841 | 5.794 | 43.165 | 2.415 |
| Total Liabilities | 7.717 | 30.472 | 137.796 | 15.006 |
| Total Long Term Debt | 0 | 0 | 0.635 | 0.235 |
| Other Liabilities, Total | 0.362 | 3.897 | 29.712 | 3.475 |
| Total Equity | 18.911 | -18.586 | -90.449 | 81.507 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | |
| Common Stock | 0.094 | 0.095 | 0.156 | 0.3 |
| Additional Paid-In Capital | 60.138 | 63.584 | 72.136 | 296.445 |
| Retained Earnings (Accumulated Deficit) | -39.797 | -80.455 | -160.562 | -215.135 |
| Treasury Stock - Common | -1.524 | -1.81 | -1.846 | 0 |
| Total Liabilities & Shareholders’ Equity | 26.628 | 11.886 | 47.347 | 96.513 |
| Total Common Shares Outstanding | 9.97635 | 9.97635 | 15.3167 | 29.9591 |
| Other Current Assets, Total | 2.338 | 0.654 | ||
| Long Term Debt | 0.635 | 0 | ||
| Other Equity, Total | -0.333 | -0.103 | ||
| Other Long Term Assets, Total | 0.106 | |||
| Current Port. of LT Debt/Capital Leases | 0.058 | |||
| Capital Lease Obligations | 0.235 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 133.498 | 119.702 | 104.393 | 91.247 | 76.239 |
| Raha ja lühiajalised investeeringud | 130.456 | 117.313 | 102.736 | 88.756 | 73.002 |
| Raha ja ekvivalendid | 130.456 | 117.313 | 102.736 | 88.756 | 73.002 |
| Laekumata arved, neto | 0 | 0 | 0 | 0.806 | 0 |
| Prepaid Expenses | 2.343 | 1.761 | 1.018 | 1.031 | 0.021 |
| Other Current Assets, Total | 0.699 | 0.628 | 0.639 | 0.654 | 3.216 |
| Total Assets | 139.2 | 125.359 | 109.94 | 96.513 | 81.258 |
| Property/Plant/Equipment, Total - Net | 4.787 | 4.776 | 4.652 | 4.437 | 4.209 |
| Property/Plant/Equipment, Total - Gross | 5.219 | 5.231 | 5.137 | 4.954 | 4.758 |
| Accumulated Depreciation, Total | -0.432 | -0.455 | -0.485 | -0.517 | -0.549 |
| Long Term Investments | 0.877 | 0.843 | 0.862 | 0.723 | 0.732 |
| Other Long Term Assets, Total | 0.038 | 0.038 | 0.033 | 0.106 | 0.078 |
| Total Current Liabilities | 16.963 | 20.524 | 17.946 | 11.296 | 10.381 |
| Accounts Payable | 6.69 | 9.307 | 7.679 | 4.71 | 3.433 |
| Accrued Expenses | 4.872 | 5.522 | 6.219 | 4.113 | 6.16 |
| Notes Payable/Short Term Debt | 0.895 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 4.506 | 5.695 | 4.048 | 2.415 | 0.728 |
| Total Liabilities | 46.757 | 48.17 | 45.426 | 15.006 | 14.056 |
| Total Long Term Debt | 0 | 0 | 0 | 0.235 | 0.219 |
| Long Term Debt | 0 | 0 | 0 | 0 | |
| Other Liabilities, Total | 29.794 | 27.646 | 27.48 | 3.475 | 3.456 |
| Total Equity | 92.443 | 77.189 | 64.514 | 81.507 | 67.202 |
| Common Stock | 0.3 | 0.303 | 0.304 | 0.3 | 0.3 |
| Additional Paid-In Capital | 292.67 | 295.636 | 298.518 | 296.445 | 296.476 |
| Retained Earnings (Accumulated Deficit) | -197.249 | -214.321 | -230.025 | -215.135 | -229.375 |
| Treasury Stock - Common | -2.991 | -4.21 | -4.21 | 0 | |
| Other Equity, Total | -0.287 | -0.219 | -0.073 | -0.103 | -0.199 |
| Total Liabilities & Shareholders’ Equity | 139.2 | 125.359 | 109.94 | 96.513 | 81.258 |
| Total Common Shares Outstanding | 29.6605 | 29.7976 | 29.9331 | 29.9591 | 29.9594 |
| Current Port. of LT Debt/Capital Leases | 0.058 | 0.06 | |||
| Capital Lease Obligations | 0.235 | 0.219 |
- Aastas
- Kvartalis
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Netotulu/algväärtus | -20.025 | -40.658 | -80.107 | -54.573 |
| Raha majandustegevusest | -8.02 | -24.589 | -22.888 | -52.643 |
| Raha majandustegevusest | 0.002 | 0.05 | 0.098 | 0.091 |
| Mittelikviidsed varad | 9.051 | 6.269 | 31.352 | 27.809 |
| Cash Taxes Paid | 0 | 0 | ||
| Makstud intressid | 0 | 0 | 0.007 | |
| Muutused tööjõus | 2.952 | 9.75 | 25.769 | -25.97 |
| Tulu investeeringutelt | 0 | -0.242 | -0.041 | -0.382 |
| Kapitalikulutused | 0 | -0.242 | -0.041 | -0.382 |
| Rahavood investeeringutelt | 31.741 | 4.89 | 52.409 | 107.171 |
| Aktsiate emiteerimine (tagasiost), neto | 28.596 | -0.375 | 20.813 | -0.617 |
| Laenu väljastamine (kustutamine), neto | 3.145 | 5.265 | 32.118 | 0.293 |
| Rahaline kogumuutus | 23.721 | -19.941 | 29.036 | 54.149 |
| Rahavoogudesse investeerimine | -0.522 | 107.495 | ||
| Muutused valuutakursside kõikumisest | -0.444 | 0.003 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -36.687 | -53.759 | -69.463 | -54.573 | -14.24 |
| Cash From Operating Activities | -12.551 | -23.082 | -38.281 | -52.643 | -15.653 |
| Cash From Operating Activities | 0.006 | 0.029 | 0.059 | 0.091 | 0.032 |
| Non-Cash Items | 21.675 | 23.505 | 25.729 | 27.809 | 0.179 |
| Changes in Working Capital | 2.455 | 7.143 | 5.394 | -25.97 | -1.624 |
| Cash From Investing Activities | -0.041 | -0.285 | -0.346 | -0.382 | 0 |
| Capital Expenditures | -0.041 | -0.285 | -0.346 | -0.382 | 0 |
| Cash From Financing Activities | 108.444 | 106.068 | 106.767 | 107.171 | -0.014 |
| Financing Cash Flow Items | -2.797 | -5.428 | -5.52 | 107.495 | 0 |
| Issuance (Retirement) of Stock, Net | 111.241 | 111.496 | 112.287 | -0.617 | 0 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0.293 | -0.014 |
| Foreign Exchange Effects | -0.003 | 0.005 | -0.011 | 0.003 | -0.087 |
| Net Change in Cash | 95.849 | 82.706 | 68.129 | 54.149 | -15.754 |
| Cash Interest Paid | 0.007 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| Vifor (International), Ltd | Corporation | 6.627 | 1995643 | 0 | 2022-04-01 | LOW |
| Venkatesan (Jay R) | Individual Investor | 6.0063 | 1808727 | 93513 | 2022-05-25 | LOW |
| EISA-ABC LLC | Corporation | 5.7191 | 1722237 | 0 | 2022-04-01 | LOW |
| Goldberg (Itzhak D) | Individual Investor | 5.2974 | 1595231 | -32082 | 2022-07-01 | LOW |
| Satterfield (Thomas A Jr) | Individual Investor | 5.2287 | 1574547 | 1574547 | 2022-05-17 | LOW |
| BVF Partners L.P. | Hedge Fund | 3.5575 | 1071297 | 0 | 2022-09-30 | LOW |
| Nantahala Capital Management, LLC | Hedge Fund | 3.54 | 1066012 | -64989 | 2022-09-30 | LOW |
| Ganzi (Victor F.) | Individual Investor | 3.25 | 978698 | 0 | 2022-04-01 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.1364 | 643360 | -127334 | 2022-09-30 | LOW |
| CM Management, LLC | Investment Advisor | 1.9924 | 600000 | 75000 | 2022-09-30 | MED |
| Park West Asset Management LLC | Hedge Fund | 1.2311 | 370724 | 295221 | 2022-09-30 | MED |
| Renaissance Technologies LLC | Hedge Fund | 0.694 | 208977 | -4523 | 2022-09-30 | HIGH |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.5811 | 175000 | 100000 | 2022-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5608 | 168887 | 81940 | 2022-09-30 | LOW |
| Millennium Management LLC | Hedge Fund | 0.4171 | 125603 | -57805 | 2022-09-30 | HIGH |
| Omenn (Gilbert S) | Individual Investor | 0.2701 | 81326 | 1000 | 2022-04-01 | LOW |
| Ergoteles Capital | Hedge Fund | 0.2619 | 78857 | -10475 | 2022-09-30 | HIGH |
| Valeo Financial Advisors LLC | Investment Advisor | 0.2114 | 63659 | 0 | 2022-09-30 | LOW |
| Raymond James & Associates, Inc. | Research Firm | 0.1992 | 60000 | 0 | 2022-09-30 | LOW |
| Birchview Capital, LP | Investment Advisor | 0.1806 | 54392 | 0 | 2022-12-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group +500000+
Kauplejad
93000+
Igakuiste aktiivsete klientide arv
$57000000+
Igakuine investeerimise maht
$31000000+
Proovige nüüd Igakuiselt välja võetud
Kauplemiskalkulaator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Kauplemise vahendustasu
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Finantsvõimendus
20:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
Angion Biomedica Corp. Company profile
Ettevõttest Angion Biomedica Corp.
Angion Biomedica Corp. on hilises staadiumis biofarmatseutiline ettevõte. Ettevõte keskendub väikesemolekulaarsete ravimite avastamisele, arendamisele ja turustamisele ägedate elundite vigastuste ja fibrootiliste haiguste raviks. Ettevõtte juhtiv tootekandidaat on ANG-3777. Ettevõtte tooteprogrammi kuuluvad ANG-3070, rho kinaas 2 (ROCK2) ja CYP11B2. ANG-3777 on hepatotsüütide kasvufaktori (HGF) mimeetikum, mida ta hindab mitme ägeda elundikahjustuse ja sellega seotud näidustuste, sealhulgas ägeda neerukahjustuse (AKI) ja teiste elundite, näiteks kopsude, kesknärvisüsteemi (KNS) ja südame kahjustuste puhul. ANG-3777'i hinnatakse ka ägeda kopsukahjustuse (ALI) näidustuste puhul, keskendudes ägeda hingamispuudulikkuse sündroomile (ARDS), samuti ägedate kesknärvisüsteemi vigastuste puhul. Ettevõtte teised programmid on fibrootiliste haiguste raviks, ANG-3070, türosiini kinaasi inhibiitor (TKI), ja rho kinaasi 2 (ROCK2) inhibiitor.
| Industry: | Biotechnology & Medical Research (NEC) |
51 Charles Lindbergh Boulevard
UNIONDALE
NEW YORK 11553
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com